High flow nasal cannula oxygen therapy, work in progress in respiratory critical care by Schreiber, A. et al.
14 Minerva Medica december 2016
extubation outcome, even in the short-term 
period. in fact, despite a successful SBT, 15-
30% of extubated patients develop acute re-
spiratory distress and require reintroduction of 
invasive mechanical ventilation (iMv) within 
48 hours.4, 5 in the postextubation period, it is 
therefore crucial to prevent or identify early 
clinical deterioration, to limit the development 
of respiratory failure. it is equally important 
to understand which category of patient can 
benefit most, from which type of treatment, 
after a planned extubation, the re-occur-rence of acute respiratory distress needing 
the restoration of invasive mechanical support 
through an endotracheal tube is a severe phe-
nomenon associated with several important 
consequences, including increased morbidity, 
intensive care Unit (icU) mortality, and an 
enormous financial burden.1-3 a spontaneous 
breathing trial (SBT) passed with no signs of 
respiratory distress is a necessary step before 
extubation but may not be enough to predict 
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after a planned extubation, the re-occurrence of acute respiratory distress needing the restoration of invasive mechanical 
support is a severe phenomenon associated with several important consequences, including increased morbidity, inten-
sive Care Unit mortality, and an enormous financial burden. So far, the most commonly used techniques to ameliorate 
gas exchange in the postextubation period were low-flow oxygen therapy and non-invasive ventilation (NIV). High flows 
through nasal cannulae (HFnc) is a system which allows increased cO2 wash-out of anatomical dead space, positive 
nasopharyngeal pressure, a relatively constant FiO2, and an improvement of mucociliary function. in a recently published 
paper by Hernandez et al. HFnc therapy, compared in the postextubation period to standard oxygen in patients at low 
risk of re-intubation, was associated with a lower re-intubation rate within 72 hours of extubation, with no evidence of 
any delays in re-intubation which may prove fatal, as previously reported in the context of niv. despite yielding some 
useful starting points and positive results with HFNC, some discrepancies have emerged in the findings of the studies 
in this field. As we await further more homogeneous and enlightening studies, at present we can only affirm that HFNC 
seems to be a useful means to prevent and treat postextubation hypoxemia. in fact no harmful or adverse effects related 
to HFnc emerged in any of the studies and globally, it was associated with better comfort and tolerance compared with 
NIV, which justifies its use as a first alternative to standard oxygen therapy.
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pneumonia, a condition associated to a scarce 
efficacy of NIV, seemed to show efficacy of 
HFnc. HFnc was associated with less dys-
pnea and mouth dryness, and greater overall 
comfort. dyspnea decrease was due to several 
factors: 1) the correction of hypoxemia, and 
the reduction in the respiratory rate; 2) the 
reduction of mouth dryness thanks to the ef-
fects of the heated humidification system; and 
3) the comfort of the interface.11 a more re-
cent study reported effects not only on comfort 
and dyspnea but also on biologic parameters. 
In fact the use of HFNC enabled a significant 
reduction of respiratory rate and a significant 
increase in oxygen saturation as measured by 
pulse oximetry, with a mild increase of PacO2, 
without affecting pH. Six patients were sec-
ondarily intubated, and 3 died in the icU. This 
technique was well tolerated for several days 
probably avoiding invasive mechanical ven-
tilation and its potential drawbacks in some 
of them.15 These promising results were con-
firmed by the Florali Study:16 treatment with 
HFnc improved the survival rate among pa-
tients with acute hypoxemic respiratory failure 
(mainly related to pneumonia), even though 
no statistic difference but just a favorable 
trend in the primary outcome (i.e. intubation 
rate) was observed with HFnc, as compared 
with standard oxygen therapy or noninvasive 
ventilation. in this cohort the rate of intuba-
tion seemed to be lower in more hypoxiemic 
patients with PaO2/FiO2 ratio lower than 200.
Effect of HFNC in the 
postextuabtion period
Maggiore et al.17 compared HFnc with 
venturi masks in 105 patients intubated for at 
least 24 hours with a PaO2/FiO2 ratio <300 at 
the end of a SBT. after 24 hours, oxygen satu-
ration (for the same FiO2 level) and PaO2/FiO2 
ratio were significantly higher in the HFNC 
group (287±74 vs. 247±81, P=0.03) with a 
lower arterial carbon dioxide and respiratory 
rate. discomfort related to the interface and 
airways dryness was also lower in the HFnc 
group. Furthermore, high-flow oxygen was 
associated with fewer episodes of desatura-
and when (i.e. immediately after extubation 
or later). in the past, the most commonly used 
techniques to ameliorate gas exchange in the 
postextubation period were low-flow oxygen 
therapy and non-invasive ventilation (niv). 
Standard low-flow oxygen was the first-line 
therapy and the only possible alternative in 
the case of inadequate hypoxemia correction, 
whilst non-invasive ventilation was mainly 
used in case of hypercapnia.4, 6-8 niv was also 
successfully used as a preventive intervention 
in patients considered at high-risk of develop-
ing postextubation respiratory failure.6, 9
High-flow through nasal cannula system
Over the past two decades, a new device 
able to deliver heated and humidified oxygen 
at high flows through nasal cannulae (HFNC) 
has been proposed, first in preterm newborns 
and the pediatric setting,10 and then in the care 
of adult patients with acute respiratory failure 
(arF).11 Gas from an air/oxygen blender that 
can generate a total flow of up to 60 L/min is 
heated and humidified with an active humidifi-
er and subsequently delivered through a heated 
circuit.12 High flow of adequately heated and 
humidified gas is considered to have a number 
of physiological effects: 1) high flow washes 
out carbon dioxide in anatomical dead space; 
2) although delivered through an open system, 
high flow overcomes resistance against expira-
tory flow and creates positive nasopharyngeal 
pressure.13 While the pressure is relatively low 
compared with closed systems, it is considered 
adequate to increase lung volume or recruit 
collapsed alveoli; 3) the difference between 
the inspiratory flow of patients and delivered 
flow is small and FiO2 remains relatively con-
stant; 4) as gas is generally warmed to 37 °c 
and completely humidified, mucociliary func-
tions remain good and a limited level of dis-
comfort is reported.14
Efficacy of HFNC in patients with 
acute respiratory failure
Preliminary studies in patients suffering 
from acute respiratory failure, mainly due to 
              COPYRIGHT
© 






















































































































































































































































































































































































































































































































































ScHreiBer HiGH FLOW naSaL cannULa OXYGen THeraPY
16 Minerva Medica december 2016
dyspnea scores, respiratory rates and heart 
rates with HFnc compared to standard oxy-
gen delivered through a mask. in contrast to 
the studies cited so far testing mask oxygen 
or low-flow nasal cannulae therapy, in a large 
multicenter randomized study, Stephan et al.22 
compared the effect of bilevel positive airway 
pressure (BiPAP) to high-flow nasal cannula 
therapy. in this non-inferiority trial patients 
were randomized to receive HFnc or BiPaP 
for at least 4 hours per day if they developed 
acute respiratory failure during or after a SBT 
or if, even not developing it, they were deemed 
at risk due to preexisting risk factors. HFnc 
did not seem to be inferior to BiPaP in terms 
of re-intubation rate. No significant differ-
ences were found in icU mortality, dyspnea, 
or comfort scores. pH and PacO2 values were 
slightly but significantly better in the HFNC 
group in the first hour after extubation, but this 
difference became irrelevant at 6 hours and on-
wards. Skin breakdown was significantly more 
common with BiPaP after 24 hours. The au-
thors concluded that the results supported the 
use of HFnc in this patient population.
in the recently published paper by Hernan-
dez et al.23 once again HFnc therapy was com-
pared in the postextubation period to standard 
oxygen, but with at least one difference from 
all of the aforementioned papers. The authors 
recruited only patients who met the criteria of 
low risk of re-intubation, according to previ-
ous literature definitions.9, 24 Patients were ran-
domized to receive either HFnc, preventively 
administrated immediately after extubation, 
or standard oxygen therapy, with the aim of 
highlighting differences in re-intubation rate, 
occurrence of postextubation respiratory fail-
ure, time to re-intubation, hospital length of 
stay and mortality. HFnc oxygen was admin-
istered for the first 24 hours and then stopped; 
flow was initially set at 10 L/min and titrated 
upward in 5 l/min-steps until patients experi-
enced discomfort; standard oxygen was ap-
plied continuously through nasal cannulae or 
non-rebreathing facemasks with the flow ad-
justed to maintain SpO2 above a preset value. 
re-intubation rate within 72 hours of extu-
bation was lower in the HFnc group versus 
tion detected on bedside monitors, interface 
displacement and fewer patients in the HFnc 
group required escalation to niv or re-intuba-
tion as compared with the venturi mask group. 
Parke et al. conducted a randomized controlled 
trial comparing HFnc vs. usual care (i.e. stan-
dard oxygen therapy) administered in the first 
48 hours after the extubation of postoperative 
cardiac surgery patients.18 The number of pa-
tients with a SpO2/FiO2 ratio ≥445 on day 3, 
which was the primary outcome, was not dif-
ferent between the two groups (46.4% in the 
HFnc group vs. 42.4% in the standard care 
group, P=0.45), whereas PacO2 at 4 hours 
postextubation and escalation in respiratory 
support were slightly but significantly lower in 
the HFnc group vs. the standard care group. 
Similarly, in patients who had undergone car-
diac surgery, with a BMI of ≥ 30 kg/m2, corley 
et al.19 assessed the effects of HFnc delivered 
immediately after extubation on postoperative 
atelectasis formation and respiratory function, 
in comparison to standard oxygen therapy 
care. For the primary outcome of atelectasis, 
no evidence of any difference between treat-
ment and control groups was found. Likewise, 
no difference was found in the PaO2/FiO2 ratio 
in the first 24 hours after extubation. However, 
when different time periods were analyzed 
separately, the mean PaO2/FiO2 ratio in the 
first 8 hours after extubation was significantly 
higher in the standard oxygen group. no differ-
ence was found in failure of allocated therapy 
and requirement of an escalation of respiratory 
support within the first 24 hours. There was 
statistically but not clinically less dyspnea in 
the standard group in comparison to the HFnc 
group. Tiruvoipati et al.,20 conducted a small 
randomized crossover trial comparing short-
term interventions (30-min HFnc vs. 30-min 
non rebreathing mask), and found no signifi-
cant differences in gas exchange or respiratory 
rate between the two therapeutic strategies. 
However, greater comfort was associated with 
the high-flow nasal cannula. Another similar 
randomized crossover trial showed the same 
trend toward greater comfort with HFnc 21 
but, differently from the first one, it was able 
to show a significant reduction in patients’ 
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whereas in others they were enrolled. Further-
more, some demographic and clinical parame-
ters at enrollment, such as arterial blood gases, 
previous use of domiciliary oxygen and/or me-
chanical ventilation, are sometimes not avail-
able, precluding the possibility of evaluating 
the comparability of different patient popula-
tions.20, 21, 28
Other differences emerge in the protocols 
used. in the majority of the studies cited, 
treatments were allocated immediately after 
extubation,17-19, 21, 23 whereas in the study by 
Tiruvoipati20, patients were randomized to 
the first intervention 30 min after extubation 
and, finally, in the study by Stephan et al. 22 
the therapeutic protocol was heterogeneous 
and it was applied at different times during the 
study period. in fact, in the latter study, some 
patients were eligible for randomization if 
they failed a SBT, others if a successful SBT 
was followed by failed extubation and others 
only in the presence of preexisting risk factors 
(without the need for any sign of respiratory 
failure during or after the SBT).
even the studies in which the therapeutic 
device was applied at the same moment (i.e. 
immediately after extubation) show several 
important differences in patients’ inclusion cri-
teria. in fact, the eligibility criterion was in one 
case a PaO2/FiO2≤300 at the end of a SBT,17 
the fulfillment of the criteria of high risk of re-
intubation in other two cases (i.e. postcardiac 
surgery in Parke,18 postcardiac surgery plus 
obesity in corley19), and in another one, the 
absence of a prori risks for re-intubation (i.e. 
patients at low risk).23
variability also concerns device application 
time and time of the evaluation of the clinical 
effects and outcomes. in most cases, HFnc 
was applied for 48 consecutive hours,17, 18 but 
sometimes until patients’ discharge from the 
icU,17 occasionally only for the first 24 hours 
due to planned icU discharge and the impossi-
bility of continuing HFnc in general wards,23 
or even for a minimum of 8 hours (without 
specification of the maximum).19 in the trial by 
Stephan et al.,22 HFnc was discontinued not 
at a predetermined time but when SaO2 was 
at least 95% at 6 L/min or the PaO2/FiO2 ratio 
the standard therapy group (4.9% vs. 12.2% 
respectively, P=0.004) and similarly postex-
tubation respiratory failure was less common 
in the high-flow group (8.3% vs. 14.4% of the 
standard oxygen group, P=0.03). differences 
in other secondary outcomes were not statisti-
cally significant. The absence of any dissimi-
larity in median time to re-intubation appears 
to be particularly relevant. In fact, this finding 
suggests that the application of HFnc was not 
associated with a delay in re-intubation which, 
in some cases, may prove fatal, as previous-
ly reported by other authors in the context of 
niv 25 and also, more recently, HFnc.26 The 
immediate implication of the results of the 
study of Hernandez et al. is that at present, 
high-flow oxygen, for the category of patients 
with a low a priori risk of re-intubation, has 
probably to be considered not only a better 
choice in comparison to standard oxygen, but 
also the best currently available therapeutic 
option. in fact, when administrated preven-
tively in the postextubation period, niv has 
failed to demonstrate an effect on postextuba-
tion failure in the general population of criti-
cally ill patients, showing a protective effect 
only in specific categories of patients at high 
risk of re-intubation.9, 24, 27
Limitations of the studies focused 
on the effect of HFNC in the 
postextuabation period
despite yielding some useful starting points 
and positive results with HFnc, some dis-
crepancies have emerged in the findings of the 
aforementioned studies, prevalently in terms 
of efficacy in improving gas exchange and 
avoiding desaturations, preventing escalation 
of respiratory support and re-intubation and in 
promoting comfort and tolerance. These dis-
crepancies could be explained by some of the 
differences and variability among the studies.
The first difference lies in patients’ baseline 
characteristics. The comparability of patients 
of different studies and sometimes even within 
the same study may be questionable. in some 
cases, patients with preexisting chronic respi-
ratory diseases, such as cOPd, were excluded, 
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factor are provided in any of the studies re-
ported herein. incidentally, even the oxygen 
used in control groups was extremely hetero-
geneous, both in terms of the type of device 
and the flow set. Sometimes different devices 
were used in the same study and even in the 
same patients, as they could receive oxygen 
via face mask immediately after extubation 
and then be switched to nasal cannulae in the 
following 24 hours and sometimes the type of 
oxygen device and the flow was not recorded 
after 24 hours.23 consequently, in many cases 
FiO2 was neither truly reliable nor known in 
the control groups.
There is evidence of discrepancies even in 
the definition and assessment of comfort of the 
different devices. comfort is an extremely im-
portant issue as it may affect the final efficacy 
of a therapeutic device. in fact, even in the 
setting of niv, intolerance related to interface 
discomfort was enumerated as one of the most 
common reasons for failure.34 What Parke et 
al.18 affirm may well be true, namely, that the 
more critical the patients, the better they tol-
erate HFnc. in fact, patients suffering from 
acute respiratory failure with a high respira-
tory flow demand gain can benefit more from 
HFnc and consequently tolerate it better in 
comparison to less dyspnoeic patients. How-
ever, it is also true that some differences may 
be related to the fact that comfort and toler-
ance are not univocally defined in the different 
studies. Sometimes discomfort is specified as 
related to interface and to symptoms of mouth 
and throat dryness, difficulty to swallow and 
throat pain,17 in some other cases it is not de-
fined and it is assessed more generally. Some-
times it is reported by the patients themselves 
and in other cases it is assessed by a nurse by 
the means of a visual analogue scale.
Conclusions
a consolidated experience in the applica-
tion of HFnc to prevent or treat postextuba-
tion failure in adults is still lacking. as we 
await further more homogeneous and enlight-
ening studies in this context, as proposed by 
Scala,28 HFnc may be seen as an additional 
was ≥300 and, finally, in the two crossover tri-
als,20, 21 nFnc was administered for only 30 
minutes just before or just after standard oxy-
gen. concerning the primary clinical outcome 
and time of its evaluation, for Maggiore et al. 
it was assessed at 24h when HFnc was still 
ongoing, for Parke at day 3 after surgery, when 
HFnc had already been stopped, and likewise 
in the study by Hernandez, as re-intubation 
was assessed at 72 hours after extubation while 
HFnc was stopped at 24.
HFNC flow rate also varied, ranging from 
30 L/min20 to 50 L/min 17, 22 and was some-
times started at an extremely low value (10 
L/min), more typical of a low-flow device, 
and augmented until the occurrence of pa-
tient discomfort, but without a specified in-
ferior limit.23 This factor has probably played 
an important role in determining the different 
measurable effects of HFnc and the different 
outcomes. in fact, the well-known PeeP effect 
of HFnc strictly depends on and is directly 
proportional to the set flow rate.29, 30 also, 
higher flow rates may have a greater effect on 
washout of nasopharyngeal dead space and in 
reducing the fraction of inspired cO2,31, 32 in 
minimizing the entrainment of room air with 
the supplemental oxygen,33 and in assuring 
a higher delivered FiO2. Furthermore, in the 
study by Parke et al. an airvOTM humidifier 
(Fisher and Paykel Healthcare Ltd, auckland, 
new Zealand) was used, whereas in the other 
studies an 850 OptiflowTM system was applied 
(rT202 delivery tubing and Mr850 heated 
humidifier, Fisher and Paykel Healthcare, 
auckland, new Zealand). This could represent 
an additional source of variability in terms of 
flow and oxygen delivered.
Similarly, all the studies mentioned did not 
consider the role of open-mouth breathing. Pa-
tients’ attitude of prevalently maintaining the 
mouth open or closed while breathing may 
have further increased the variability among 
the studies. Open-mouth breathing during 
HFnc lowers delivered FiO2 compared with 
closed-mouth nasal breathing due to mixing 
of the high-flow nasal oxygen with room air 
inhaled through the mouth,33 and significantly 
reduces the PeeP effect.29 no data about this 
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step, a further chance in the available thera-
peutic options. as brilliantly highlighted in 
the editorial by Spoletini et al.,32 the existing 
studies on the topic, first of all the study by 
Hernandez et al., raise more questions than 
answers. What are the optimal settings and the 
best durations of use of HFnc in the postop-
erative or postextubation setting? When is the 
best time to apply it — preventively or after 
the occurrence of failure? Which could be the 
best alternation? Should we expect to see ben-
efits in alternating between HFNC and NIV? 
When should we remove it? and many oth-
ers. Presently, from the available literature in 
this specific setting, we can only affirm that 
HFnc seems to be a useful means to prevent 
and treat postextubation hypoxemia. in fact, 
despite all of the aforementioned discrepan-
cies, no harmful or adverse effects related to 
HFnc emerged in any of the studies and glob-
ally, it was associated with better comfort and 
tolerance compared with NIV, which justifies 
its use as a first alternative to standard oxygen 
therapy.
Riassunto
Dopo un’estubazione programmata, il riverificarsi di un 
episodio di insufficienza respiratoria acuta che necessiti di un 
supporto ventilatorio meccanico invasivo è un grave fenomeno 
associato a molteplici importanti conseguenze, tra le quali un 
aumento della morbilità, della mortalità in Terapia intensiva, 
e un enorme onere finanziario. Finora le tecniche più utilizzate 
per migliorare gli scambi gassosi nel periodo postestubazio-
ne sono state l’ossigenoterapia a bassi flussi e la ventilazione 
meccanica non invasiva (non-invasive ventilation, NIV). L’os-
sigenoterapia ad alti flussi attraverso cannule nasali (high flows 
through nasal cannulae, HFnc) rappresentano un sistema che 
consente di aumentare il wash-out cO2 nello spazio morto ana-
tomico, a livello nasofaringeo, il mantenimento di una FiO2 re-
lativamente costante e un miglioramento della funzione muco-
ciliare. in un articolo recentemente pubblicato da Hernandez et 
al. l’ossigenoterapia con HFNC rispetto all’ossigeno standard 
nel periodo postestubazione in pazienti a basso rischio di re-
intubazione, è stato associato ad un tasso inferiore di nuova in-
tubazione entro 72 ore dalla estubazione, senza alcuna evidenza 
di eventuali ritardi nella re-intubazione che potessero rivelarsi 
fatali, come precedentemente riportato in caso di utilizzo del-
la NIV. Nonostante l’HFNC abbia fornito alcuni utili punti di 
partenza e risultati positivi, sono emerse alcune discrepanze nei 
risultati degli studi svolti in questo campo. in attesa di ulteriori 
studi, più omogenei e chiarificatori, al momento possiamo solo 
affermare che l’HFNC sembra essere uno strumento utile per 
prevenire e curare l’ipossiemia nel periodo postestubazione. In 
effetti, a oggi non sono emersi effetti dannosi o negativi rela-
tivi all’utilizzo di HFNC in nessuno degli studi e in generale 
nel mondo ed è stato associato a un comfort e una tolleranza 
maggiori rispetto alla NIV, che ne giustifica il suo utilizzo come 
prima alternativa all’ossigenoterapia standard.
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